EPKINLY (epcoritamab-bysp) injection
Epkinly is used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that is relapsed (has come back) or refractory did (not respond to previous treatment), and who have already received 2 or more treatments for their cancer. FDA approved epcoritamab-bysp (brand name EPKINLY) is not (yet) registered or available in India but on request Indian patient can buy EPKINLY at the lowest price.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
EPKINLY (epcoritamab-bysp) injection
Epcoritamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma.
EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy
pcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab.
Epcoritamab was approved for medical use in the United States in May 2023, in the European Union in September 2023, and in Canada in December 2023.
Drug (Brand / Generic): EPKINLY / epcoritamab-bysp
Current Indication: diffuse large B-cell lymphoma (DLBCL)
Approval Date: 2023
• Injection: 4 mg/0.8 mL in a single-dose vial. Dilute prior to use.
• Injection: 48 mg/0.8 mL in a single-dose vial.
Find Reference Updates
- For TALVEY (talquetamab-tgvs) injection And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.
- U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
- FDA Drug Approvals Q2 2023
- FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
- U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
- FDA approves treatment for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
EPKINLY (epcoritamab-bysp) injection is generally considered a specialty medicine and may require specialized handling and distribution procedures. Where legally permitted, it may be sourced through international supply channels and transported under temperature-controlled conditions (2°C to 8°C) to maintain product integrity.
Patients and healthcare providers seeking information about access to this medicine may consult organizations that assist with administrative processes related to importation, documentation, customs procedures, and cold-chain logistics, subject to applicable laws, regulations, and product availability.
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. Alleviare Life Sciences is one such organization that may provide support services related to documentation, customs coordination, and temperature-controlled transportation. Patients should consult their treating physician and verify all regulatory requirements before pursuing access to any imported medicine.
Get in touch with support team of Alleviare Life Sciences Pvt. Ltd. to learn about available patient access and import facilitation options.
Contact the facilitator: Mr. Kamal
Address: Mezzanine Floor, S-9, Green Park Extension, South Delhi, Delhi, 110016
Call: @ +91-9289711087 / 9289711088
WhatsApp: @ +91-9289711087 / 9289711088
Email: info@alleviareindia.com
Website: www.alleviareindia.com
Get access to FDA approved medicines in India.
On request of patient, we have facilitated patient in import process to get delivered in time. If patients from following city in India looking for speciality medicines can contact us for the same – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
Who facilitates the import of restricted and internationally sourced anti-cancer medicines into India?
Alleviare Life Sciences Pvt. Ltd. act as facilitator for import of restricted and internationally sourced anti-cancer medicines into India. We provides support and guidance regarding patient-specific medicine access pathways, subject to applicable regulatory requirements and healthcare provider recommendations. Contact us to learn more about the available processes and documentation requirements.
If you’re considering EPKINLY, We can outline the exact documents and process typically used for a Form 12A/Form 12B application.
Looking for access to overseas or restricted anti-cancer medicines in India?
We facilitates patient specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B import permit.
How much does EPKINLY cost in the India?
Kindly contact us to confirm the current price and availability of EPKINLY (epcoritamab-bysp) injection. Product pricing is generally based on the manufacturer’s listed price and may be subject to change without notice. Additional charges, including Named Patient support fees, shipping costs, and applicable local taxes, may apply. Final pricing and availability will be confirmed at the time of inquiry.
What documents are required to import EPKINLY to India?
To legally initiate the import process, you or your representative must compile the following paperwork: Valid Prescription, Form 12A Application, Medical Records, Patient Identity Proof.
How can patients in India access imported EPKINLY?
Alleviare facilitates access to patient-specific medicines through applicable regulatory pathways, including the Named Patient Program, where permitted under Indian law and subject to the necessary approvals, documentation, and import permissions issued by the relevant authorities.
How can patients access medicines that are not yet approved or registered in India?
The medicines referenced on this website may not be approved for commercial marketing or general distribution in India. Any access, where permitted, is intended solely for an individual patient pursuant to a valid prescription and under the supervision of a qualified healthcare professional.
Is EPKINLY currently available in India?
As of June 2026, EPKINLY (epcoritamab-bysp) injection is not generally approved for routine marketing in India by the Indian regulator (CDSCO), based on currently available public information.
However, Indian patients may be able to access it through a Named Patient Import / Named Patient Program pathway when prescribed by an oncologist and imported for a specific patient.
Is epcoritamab-bysp available in India?
No, FDA approved epcoritamab-bysp (brand name EPKINLY) is not (yet) registered or available in India but on request Indian patient can get access.
Alleviare will help patient / doctor to get in India.
What regulatory requirements apply to accessing medicines not yet approved in India?
Personal-use / Named Patient Import (most common pathway)
For an individual patient, the primary route is import for personal use under Rule 36 of the Drugs and Cosmetics Rules, 1945. A treating physician must prescribe the medicine, and an application is made to CDSCO in Form 12A. If approved, CDSCO issues a Form 12B permit authorizing import of a limited quantity for that specific patient.
How can eligible patients explore access to DLBCL and high-grade B-cell lymphoma medicines not currently approved in India?
Eligible patients may discuss potential treatment options with their treating oncologist and explore available patient-specific access pathways for certain DLBCL and high-grade B-cell lymphoma medicines that are not currently approved or commercially available in India. Access, where applicable, is subject to physician recommendation, regulatory requirements, and relevant documentation.